Risperdal Consta is believed to be the first long-acting atypical antipsychotic to be available in Japan. Janssen Pharmaceutica KK expects to launch the product in Japan promptly after its listing on Japan’s National Health Insurance drug price standard.
Under the development and supply agreement between Janssen-Cilag and Alkermes for Risperdal Consta, Janssen-Cilag is responsible for worldwide sales and marketing of the product. Alkermes is responsible for worldwide manufacturing and receives manufacturing fees and royalties on product sales.
Risperdal Consta is a long-acting injectable form of risperidone that was developed utilizing Alkermes’s Medisorb drug-delivery technology.
David Broecker, CEO of Alkermes, said: “The approval of Risperdal Consta in Japan represents another important market opportunity for the product. As the first and only long-acting atypical antipsychotic approved for use in Japan, Risperdal Consta could provide a valuable new treatment option for patients managing this serious, chronic disease.”